Featured Research

from universities, journals, and other organizations

Digoxin tied to increased risk of death in patients with atrial fibrillation

Date:
August 11, 2014
Source:
Stanford University Medical Center
Summary:
In 'An Account of the Foxglove and Some of its Medical Uses,' published in 1785, Sir William Withering cautioned readers that extracts from the plant foxglove, also called digitalis, was not a perfect drug. 'Time will fix the real value upon this discovery,' he wrote. Now, more than 200 years later, researchers have validated Withering's warning with the discovery that patients with atrial fibrillation who are treated with the digitalis-derivative digoxin are more likely to die than similar patients who received different treatments.

Digoxin is extracted from the foxglove plant.
Credit: Don Henise

In An Account of the Foxglove and Some of its Medical Uses, published in 1785, Sir William Withering cautioned readers that extracts from the plant foxglove, also called digitalis, was not a perfect drug. "Time will fix the real value upon this discovery," he wrote.

Related Articles


Now, more than 200 years later, researchers at the Stanford University School of Medicine have validated Withering's warning with the discovery that patients with atrial fibrillation -- a rapid and irregular heart rhythm -- who are treated with the digitalis-derivative digoxin are more likely to die than similar patients who received different treatments.

"The take-home point is to question whether people should really be on this drug," said the study's lead author, Mintu Turakhia, MD, assistant professor of cardiology at Stanford and director of cardiac electrophysiology at the Veterans Affairs Palo Alto Health Care System. "These data challenge the current guidelines."

The study will be published online Aug. 11 in the Journal of the American College of Cardiology, and will appear in the Aug. 19 print issue of the journal.

Turakhia and his team analyzed records from 122,465 patients who received a new diagnosis of atrial fibrillation from the U.S. Department of Veterans Affairs health-care system between 2003 and 2008. Doctors prescribed digoxin to 23 percent of the patients, and 70 percent of those patients were still on the drug one year later. Patients treated with digoxin were 1.2 times more likely to die than comparable patients prescribed other therapies. Patients receiving digoxin were more likely to die regardless of age; use of other drugs such as beta-blockers, amiodarone or warfarin; or the presence of other factors such as kidney disease, heart attack or heart failure, the study found.

"This is going to be as close to proof positive as we get because we may never have a randomized trial of this drug," Turakhia said. Pharmaceutical companies lack the incentive to finance studies on a long-accepted, generic drug.

Although recent studies showed mixed results, doctors and patients trusted digoxin because of its historic status, Turakhia said.

"There's an evidence gap," he said, adding that he launched the investigation because digoxin hasn't been rigorously tested like the many other atrial fibrillation treatment options.

The VA patient pool was predominantly male -- only 1,980, or 1.6 percent, were female -- and Turakhia has called for additional studies to establish whether the results are applicable to women as well.

Turakhia said many other drugs with better safety results are available to treat atrial fibrillation. Digoxin slows the heart rate but does not correct it to a normal rhythm. "We are not asserting this drug should never be used," he said. "However, in light of the many other drugs that can be used to slow down the heart rate in atrial fibrillation, patients and providers need to ask whether digoxin should be the treatment of choice when there are other, safer drugs. "


Story Source:

The above story is based on materials provided by Stanford University Medical Center. The original article was written by Becky Bach. Note: Materials may be edited for content and length.


Journal Reference:

  1. Mintu P. Turakhia, Pasquale Santangeli, Wolfgang C. Winkelmayer, Xiangyan Xu, Aditya J. Ullal, Claire T. Than, Susan Schmitt, Tyson H. Holmes, Susan M. Frayne, Ciaran S. Phibbs, Felix Yang, Donald D. Hoang, P. Michael Ho, Paul A. Heidenreich. Increased Mortality Associated With Digoxin in Contemporary Patients With Atrial Fibrillation. Journal of the American College of Cardiology, 2014; 64 (7): 660 DOI: 10.1016/j.jacc.2014.03.060

Cite This Page:

Stanford University Medical Center. "Digoxin tied to increased risk of death in patients with atrial fibrillation." ScienceDaily. ScienceDaily, 11 August 2014. <www.sciencedaily.com/releases/2014/08/140811170102.htm>.
Stanford University Medical Center. (2014, August 11). Digoxin tied to increased risk of death in patients with atrial fibrillation. ScienceDaily. Retrieved October 25, 2014 from www.sciencedaily.com/releases/2014/08/140811170102.htm
Stanford University Medical Center. "Digoxin tied to increased risk of death in patients with atrial fibrillation." ScienceDaily. www.sciencedaily.com/releases/2014/08/140811170102.htm (accessed October 25, 2014).

Share This



More Health & Medicine News

Saturday, October 25, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Texas Nurse Nina Pham Cured of Ebola

Texas Nurse Nina Pham Cured of Ebola

AFP (Oct. 25, 2014) — An American nurse who contracted Ebola while caring for a Liberian patient in Texas has been declared free of the virus and will leave the hospital. Duration: 01:01 Video provided by AFP
Powered by NewsLook.com
IKEA Desk Converts From Standing to Sitting With One Button

IKEA Desk Converts From Standing to Sitting With One Button

Buzz60 (Oct. 24, 2014) — IKEA is out with a new convertible desk that can convert from a sitting desk to a standing one with just the push of a button. Jen Markham explains. Video provided by Buzz60
Powered by NewsLook.com
Ebola Protective Suits Being Made in China

Ebola Protective Suits Being Made in China

AFP (Oct. 24, 2014) — A factory in China is busy making Ebola protective suits for healthcare workers and others fighting the spread of the virus. Duration: 00:38 Video provided by AFP
Powered by NewsLook.com
WHO: Millions of Ebola Vaccine Doses by 2015

WHO: Millions of Ebola Vaccine Doses by 2015

AP (Oct. 24, 2014) — The World Health Organization said on Friday that millions of doses of two experimental Ebola vaccines could be ready for use in 2015 and five more experimental vaccines would start being tested in March. (Oct. 24) Video provided by AP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:

Strange & Offbeat Stories

 

Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:  

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile iPhone Android Web
Follow Facebook Twitter Google+
Subscribe RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins